Many drug repurposing reports are available but those are mainly concentrated on a single target. The present study directed with a holistic approach of targeting multiple COVID19 proteins with a mixture of FDA approved drugs. The proposed blend drugs include Elbasvir, Ledipasvir, Paritaprevir, and Velpatasvir which currently used for HCV treatment. Inclusion anti-inflammatory Antrafenine and anti-migraine Ergotamine drugs can be effective for dual action of inflammation reduction and COVID19 inhibition. The anticipated combination of drugs acting on both non-structural and structural proteins therefore, can be able to reduce the COVID19 infection process and also reduce viral multiplication. The present study can be immediacy explore further by medical, pharm and research experts effectively to find out the best strategy for anti-COVID19 treatment.